MK-0941
CAS: 1137916-97-2
Ref. 3D-MVB91697
| 5mg | A consultar | |
| 10mg | A consultar | |
| 25mg | A consultar | |
| 50mg | A consultar | |
| 100mg | A consultar |
Informação sobre produto
MK-0941 is a potential therapeutic for the treatment of type 2 diabetes. It is a novel, orally active, small molecule that has been shown to reduce blood glucose levels in preclinical models. MK-0941 targets pancreatic and hepatic steatosis by inhibiting the uptake of triglycerides from plasma into these tissues. MK-0941 also increases insulin sensitivity in vitro and in vivo. This drug has been studied as monotherapy at doses of 0.1, 1, or 10 mg/kg and as combination therapy with metformin at doses of 5 or 25 mg/kg in db/db mice and wild-type mice. The study drug was well tolerated up to 10 mg/kg without any adverse effects on body weight or food intake observed.
MK-0941 has shown promising results in lowering blood glucose levels and improving insulin sensitivity when administered alone or in combination with metformin at high doses.
Propriedades químicas
Consulta técnica sobre: 3D-MVB91697 MK-0941
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
